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Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of
hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms
of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity
involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter
sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark
genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC
overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene
transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53,
and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation
signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of
rare DNA methylation events during the course of tumor development. This selection appears to be driven by the
genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in
tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of
human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will
allow for a more complete classification of tumors and understanding of tumor cell biology.
Citation: Opavsky R, Wang SH, Trikha P, Raval A, Huang Y, et al. (2007) CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of
tumor cells. PLoS Genet 3(9): e167. doi:10.1371/journal.pgen.0030167
Introduction
Tumor development is driven by complex patterns of
genetic and epigenetic abnormalities. A causative role for
genetic alterations in cancer has been established; however,
the signiﬁcance of what is perhaps the most common
epigenetic change associated with human and murine
malignancies, alterations in DNA methylation, is less clear
[1]. DNA methylation changes include loss of DNA methyl-
ation (hypomethylation) in repetitive sequences, which is an
event that has been linked to chromosomal instability, and
gain of DNA methylation (hypermethylation) in CpG islands,
which is associated with gene repression [2,3]. Convincing
evidence for the signiﬁcance of CpG island or promoter
hypermethylation in tumor development stems from the
observation that these events are associated with silencing of
tumor suppressor genes such as p15
INK4b, p16
INK4a, BRCA1,
VHL,o rMLH1 [3,4]. More recent studies suggest that
epigenetic mechanisms might even be involved in the
expansion of premalignant cells during the early stages of
tumorigenesis [5,6]. While CpG island methylation is asso-
ciated with the silencing of a number of cancer-related genes,
most CpG islands within the genome of the cancer cell
remain unaffected [3,7]. The mechanisms involved in deter-
mining and maintaining the speciﬁcity of CpG island
methylation during tumor development remain largely
unknown, although several explanations for this phenomena
have been provided, including differential susceptibilities of
DNA sequences [8–10], the targeting of methyltransferase
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selection for speciﬁc gene silencing events during tumor
development [14,15].
Careful statistical analysis has led to contradicting results
linking a relationship between genetic alterations and the
epigenetic proﬁle of cancer cells [16,17]. At least in colon
cancer cells, deﬁned sets of CpG island methylation events
have been weakly associated with the presence of activating
mutations in the KRAS and BRAF oncogenes as well as
inactivating mutations in the TP53 tumor suppressor gene
[18–20]. Whether similar genetic–epigenetic relationships
might exist in other cancer types is yet to be determined.
The difﬁculty in interpreting these studies lies in the fact that,
at least in part, the analysis of human tumors is confounded
by tremendous genetic variability, tumor heterogeneity, and
difﬁculties in obtaining appropriate tissue controls [21,22]. As
a result, a clear causal relationship between genetic mutation,
hypermethylation, and tumor development has remained
speculative. Here, we have taken advantage of mouse models
of T cell lymphoma to explore epigenetic alterations in
normal, premalignant, and cancer cells and demonstrate that
DNA methylation patterns are dependent on the genetic
mutation spectrum present in a tumor cell.
Results
A CpG Island Hypermethylation Signature in a Mouse
Model of T Cell Lymphoma
To study the epigenetic evolution that normal cells
experience on the path to a fully malignant state, we
exploited a bitransgenic mouse model in which inducible
MYC overexpression leads to the development of T cell
lymphomas [23]. In this system, the ﬁrst transgene contains
the human MYC cDNA under the control of the tetracycline-
responsive minimal promoter (Teto-MYC) and the second
transgene expresses the tetracycline activator protein under
the control of the immunoglobulin heavy chain enhancer and
the SRa promoter (ElSR-tTA; see Figure 1A). In the absence
of doxycycline, tTA is expressed and mediates the tran-
scription of the Teto-MYC transgene in approximately 30% of
T cells. As a result, bitransgenic mice develop immature T cell
lymphomas with lymph and splenic invasion and succumb to
disease by 5 mo of age. Overexpression of MYC is a common
feature of many human cancers, including Burkitt’s lympho-
ma. The analysis of bitransgenic ElSR-tTA;Teto-MYC mice may
thus represent a suitable mouse model to evaluate the effect
of a single oncogenic event on the epigenome of a tumor cell.
We evaluated CpG island methylation in these MYC-
induced tumors by restriction landmark genomic scanning
(RLGS), a two-dimensional gel electrophoresis that measures
the DNA methylation status of about 1,500–2,000 NotI
methylation-sensitive restriction enzyme sites preferentially
located in CpG islands [15,24]. A loss or reduction of a
radiolabeled NotI DNA fragment is indicative of DNA
methylation at that site, whereas an increase is indicative of
either hypomethylation or ampliﬁcation. Initially, we com-
pared DNA from eight late-stage lymphomas that developed
in ElSR-tTA;Teto-MYC mice and two control thymocyte
samples derived from age-matched normal ElSR-tTA mice.
This comparison revealed that 137 of 2,206 possible CpG
islands were hypermethylated in at least one tumor, with 59
loci hypermethylated in ﬁve or more tumors and seven loci
hypermethylated in all tumors (Figures 1B–1D). Statistical
evaluation using a standard goodness-of-ﬁt test indicated a
nonrandom distribution of DNA methylation (p-value ,
0.0001), which is similar to what has previously been reported
for human malignancies [15,25–27]. The identity of 79 of the
137 hypermethylated NotI/EcoRV fragments was determined
by sequencing the corresponding clones from the arrayed
NotI/EcoRV genomic library as described before [21]. Of
these, 65 corresponded to CpG islands located within 59
regions of known genes (Table S1). Southern blot analysis of
normal and tumor samples probed with the cloned DNA
fragments conﬁrmed tumor-speciﬁc hypermethylation in 14
of the 15 RLGS loci tested (Figures 1D and S1; Table S1).
Bisulﬁte sequencing and combined bisulﬁte restriction
analysis (COBRA) assays conﬁrmed tumor-speciﬁc methyl-
ation in regions surrounding the NotI site in 29 out of the 34
CpG islands tested (Figures 1E, S1, and S2; Table S1). The
discrepancy in the ﬁve CpG islands that were not conﬁrmed
by bisulﬁte-based methods may reﬂect assay-speciﬁc biases
that rely on the utilization of different restriction endonu-
clease sites. Because hypermethylation is associated with gene
silencing, we evaluated the expression of a subset of 16 genes
corresponding to the hypermethylated CpG islands identiﬁed
above. As determined by real-time reverse transcriptase PCR
(RT-PCR) techniques, the expression of 15 from 16 randomly
selected genes was signiﬁcantly decreased in tumor samples
relative to normal controls (Figures 1F and S1; Table S1).
Together, these results identify a CpG island hypermethyla-
tion signature in a mouse MYC-induced lymphoma model
that is associated with transcription repression and that has a
similar frequency of altered methylation as previously found
in human tumors [15].
Absence of Aberrant DNA Methylation in Precancerous
Cells
To determine whether this tumor-speciﬁc methylation
signature is established early in the neoplastic process, we
examined MYC overexpressing cells in young mice prior to
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Author Summary
Genetic and epigenetic alterations of the genome are common
features of cancers. The relationship between these two types of
alterations, however, remains unclear. One type of epigenetic
m o d i f i c a t i o n — D N Am e t h y l a t i o ni np r o m o t e rs e q u e n c e so f
genes—is of particular interest, since tumor cells have different
patterns of promoter methylation than normal cells. Previous
studies on human tumor samples have suggested a link between
genetic alterations and the induction of aberrant DNA methylation;
however, this link has been difficult to rigorously assess because of
the incredible genetic heterogeneity found in human cancer. In this
study, a mouse model of T cell lymphoma was used to explore the
relationship between genetic and epigenetic modifications experi-
enced by tumor cells. By introducing defined genetic changes into
preneoplastic T cells of mice, such as the overexpression of the MYC
oncogene and the ablation of tumor suppressor genes, we could
carefully evaluate how these genetic changes impacted promoter
methylation profiles during development of lymphomas in vivo. We
found that the introduction of different genetic insults resulted in
unique and diagnostic profiles of promoter methylation. Under-
standing how these methylation signatures contribute to tumor
progression could eventually have diagnostic, prognostic, and
therapeutic value for human cancers.Figure 1. Signature of Aberrant DNA Methylation in MYC-Induced T cell Lymphomas
(A) Schematic representation of transgenes in MYC-induced T cell lymphoma model used in this study.
(B) Examples of RLGS profiles obtained from normal ElSR-tTA thymocytes (normal) and ElSR-tTA;Teto-MYC tumors (tumor). Loss or decreased intensity
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of overt disease, as well as in mice manifesting early
symptoms of disease (Figure 2A and unpublished data). At
21 and 31 d of age, bitransgenic mice are asymptomatic and
the Teto-MYC transgene is expressed in only a portion (;30%)
of total thymocytes (unpublished data). By 42 d of age, the
vast majority of mice show early signs of tumor progression,
such as increased thymic cellularity and changes in the
expression of cell surface markers such as CD4, CD8, and
CD3. To enrich for MYC-expressing cells and minimize
contamination from normal T cells, bitransgenic mice were
interbred with Teto-Cre;Rosa26LOXP
EGFP reporter mice to
yield ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP
EGFP quadruple
transgenic offspring (Figure 1A). Cre expression from the
Teto-Cre transgene results in the excision of the ‘‘stop
cassette’’ located upstream of the Rosa26LOXP
EGFP locus
and synthesis of EGFP. Thus, accumulation of tTA (from
ElSR-tTA) activates the Teto-MYC and Teto-Cre transgenes and
leads to the simultaneous expression of MYC, Cre, and EGFP
within the same subpopulation of T cells. As shown in Figure
2B, ﬂuorescent activated cell sorting (FACS)-based cell
sorting of thymocytes isolated from 21-, 31- and 42-d-old
quadruple transgenic mice resulted in the efﬁcient separation
of EGFP-positive and EGFP-negative thymocytes. As ex-
pected, there was a marked enrichment of MYC expression
as well as one of its bona ﬁde transcriptional targets, nucleolin,
in EGFP-positive cells (Figures 2C, S4A and S4D). Surpris-
ingly, the RLGS patterns of DNA methylation in three pairs
of EGFP-positive and EGFP-negative cells derived from 21-,
31- and 42-d-old mice were identical, indicating that MYC
overexpression in thymocytes is not sufﬁcient to target
hypermethylation to speciﬁc CpG islands (Figure 2D and
2E; unpublished data). The absence of aberrant promoter
methylation at these early stages of disease was conﬁrmed by
gene-speciﬁc COBRA assays (Figures 2F and S3A–S3C).
Because promoter methylation can potentially represent a
consequence of long-term repression, we measured during
these early stages of lymphomagenesis the expression of genes
that are typically repressed at late stages of disease. Analysis
of EGFP-negative and EGFP-positive thymocytes isolated
from 21-, 31- and 42-d-old ElSR-tTA;Teto-MYC;Teto-Cre;Ro-
sa26LOXP
EGFP mice revealed no signiﬁcant differences in the
expression of the thirteen genes evaluated by real time PCR
assays (Figures 2G, S4B, and S4E). The fact that aberrant DNA
methylation and gene repression can only be detected during
late stages of MYC-induced lymphomagenesis, once a pre-
tumor cell has clonally expanded to the entire thymus and/or
the periphery, suggests that rare DNA methylation events
arise (or are selected for) during the course of tumor
development and are not a direct consequence of MYC
over-expression.
Overlapping CpG Island Hypermethylation Signatures
Selected During In Vitro and In Vivo Transformation of
Mouse Embryonic Fibroblasts
Lymphomas are thought to arise from the expansion of a
small pool of cancer-initiating cells [28]. Because the cellular
compartment from which tumor cells arise has not been
deﬁned in the ElSR-tTA;Teto-MYC model, it is impossible to
ascertain the DNA methylation status of the genome in these
cells. Thus, to evaluate CpG island methylation in a more
homogenous and experimentally amenable cell system where
the chronology of aberrant DNA methylation could be better
evaluated during the early neoplastic process, we turned to
mouse embryonic ﬁbroblasts (MEFs). Primary MEFs have the
potential to be transformed in vitro and in vivo by the
cointroduction of two oncogenes. We thus compared DNA
methylation by RLGS methods in primary MEFs before and
immediately after their transformation with MYC and an
activated form of Ras (Ras
61L). This comparison of 1,635 NotI
restriction sites revealed no methylation changes between
control and fully transformed MYC/Ras
61L-expressing cells
(Figure 3A–3C), suggesting that as in ElSR-tTA;Teto-MYC
mice, MYC expression and transformation of MEFs is not
sufﬁcient to target methylation to speciﬁc CpG islands. We
then assessed whether signatures of CpG island methylation
could be acquired or selected for when transformed MEFs are
cultured for longer periods of time. DNA methylation was
analyzed in MYC/Ras
61L-transformed MEFs that were either
cultured in vitro for several weeks or were injected into nude
mice for an equivalent length of time (Figure 3A). Approx-
imately 17 NotI sites were found to be hypermethylated in
MYC/Ras
61L-transformed MEFs cultured in vitro and an
additional seven NotI sites were hypermethylated in tumor
cells that emerged in the injected nude mice (Figure 3B and
3C). These data suggest that among all Myc/Ras
61L-expressing
MEFs with a fully transformed phenotype, only those with a
speciﬁc pattern of methylated CpG islands are favored during
their in vitro or in vivo expansion. The additional DNA
methylation events observed in tumors in nude mice
presumably reﬂect the additional level of selection pressure
of single-copy NotI fragments in the tumors, relative to several neighboring unaltered fragments, was detected by visual inspection of overlaid
autoradiographs. The arrows indicate the position of RLGS fragments 4E41, 2E46, 4B22, and 4D09, which are lost or reduced in intensity in tumor
samples, indicative of specific methylation events.
(C) Summary of the frequency of methylation events observed in eight tumor samples and two normal thymic controls. Filled boxes indicate
methylation at that site and open boxes indicate no methylation. Only data for RLGS fragments that have been methylated in more than 50% of tumors
are shown. Methylation data from the analysis of three sets of EGFP-positive and EGFP-negative thymocytes isolated from 21-d-old ElSR-tTA;Teto-
MYC;Teto-Cre;Rosa26LOXP
EGFP mice are also shown (see text and Figure 2).
(D) Southern blot analysis of control and tumor cells using the 2C51 NotI-EcoRV DNA fragment as a probe. DNA isolated from thymocytes of ElSR-tTA
mice was digested either with EcoRV alone (lane 1) or with EcoRV and NotI (lanes 2 and 3). DNA isolated from eight different T cell lymphomas (tumors;
lanes 1–8) was digested with restriction enzymes EcoRV and NotI. The bands represent methylated (M) or unmethylated (U) NotI sites.
(E) Schematic representation of a CpG island located near the RLGS fragment 3F56. Nucleotide position of the NotI site (black triangle), exon 1, and the
region amplified for bisulfite sequencing is indicated relative to the transcription initiation site. Bisulfite sequencing was performed on DNA isolated
from two normal and seven tumor samples. Each circle represents a CpG dinucleotide and each row of circles indicates the sequence of an individual
allele. Filled black circles correspond to methylated CpG dinucleotides and open circles represent unmethylated CpG dinucleotides.
(F) Expression of genes near the RLGS fragments 2C51 and 3F56 was quantified in thymocytes isolated from three ElSR-tTA mice (open bars) and eight
ElSR-tTA;Teto-MYC tumors (black bars) using real-time RT-PCR. The y-axis represents fold decrease in gene expression relative to the levels of gene
expression detected in the first control.
doi:10.1371/journal.pgen.0030167.g001
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(A) Schematic representation of experimental design used in this study.
(B) ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP
EGFP mice were harvested at 21 d of age, and EGFP-positive and EGFP-negative thymocytes were isolated
using high-speed FACS. Flow diagrams for nontransgenic controls (EGFP-control), as well as for ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP
EGFP thymocytes
PLoS Genetics | www.plosgenetics.org September 2007 | Volume 3 | Issue 9 | e167 1761
Hypermethylation and Genetic Makeup of Tumorsthat MYC/Ras
61L-transformed cells were exposed to in the in
vivo setting.
Tumor Suppressor Function Drives the Specificity of CpG
Island Methylation
Aberrant DNA methylation in T cell tumors could result
from rare random events selected for in neoplastic cells, from
speciﬁc defects in the DNA methylation process, from
intrinsic sequences predisposing to DNA methylation, or a
combination of all three. Genes that are methylated and
silenced in cancer are likely to be involved in speciﬁc
pathways impacting any number of important processes,
including proliferation, differentiation, and apoptosis. We
reasoned that if DNA methylation events are selected for in
neoplastic cells, and therefore contribute to the neoplastic
process, the inactivation of key tumor suppressors impacting
one or more of these same processes might diminish the
selective pressure imposed during neoplastic progression.
The inactivation of tumor suppressor function would thus be
predicted to change the speciﬁc DNA methylation signature
acquired by tumor cells.
To test this prediction, we evaluated CpG island methyl-
ation in T cell lymphomas that developed in ElSR-tTA;Teto-
MYC animals deleted for the p53, Pten, or E2f2 tumor
suppressors. P53 and PTEN are the most frequently inacti-
vated tumor suppressor genes in human cancer [29,30] and
have been shown to have tumor suppressor function in T cells
[31,32]. Recent studies in our laboratory indicate that E2f2
expression is signiﬁcantly decreased in a number of human
hematopoietic malignancies and its loss in mice accelerates T
cell lymphomagenesis (G. L., unpublished data). Therefore, we
interbred ElSR-tTA;Teto-MYC and p53
 /  or E2f2
 /  mice to
generate cohorts of ElSR-tTA;Teto-MYC;p53
 /  and ElSR-
tTA;Teto-MYC;E2f2
 /  animals. Because germ line inactivation
of Pten results in embryonic lethality, ElSR-tTA;Teto-MYC
mice were interbred with mice carrying the Teto-Cre transgene
and a conditional allele of Pten (Teto-Cre;Pten
LoxP). From these
latter crosses we generated cohorts of ElSR-tTA;Teto-MYC;Te-
to-Cre;Pten
LoxP/LoxP mice. Consistent with their tumor suppres-
sor functions, loss of p53, Pten,o rE2f2 signiﬁcantly
accelerated disease progression (p ¼ 0.001; p ¼ 0.005, and p
¼0.0007, respectively; Figure 4A). In each case, FACS analysis
conﬁrmed that lymphomas in these mice were of T cell origin
and consisted of either CD4 single- or CD4/CD8 double-
positive cells (Figure 4B). We then analyzed the pattern of
CpG island methylation in each tumor cohort by RLGS
(Figures 4C and 5A). All four tumor groups had signiﬁcant
amounts of promoter hypermethylation; with an average of
1.8% of CpG islands hypermethylated in the ElSR-tTA; Teto-
MYC cohort, 1.1 % in ElSR-tTA; Teto-MYC; p53
 /  cohort (p ¼
0.06), 0.3% in ElSR-tTA; Teto-MYC; Teto-Cre;Pten
LoxP/LoxP (p ¼
0.004), and 1.9% in ElSR-tTA; Teto-MYC; E2f2
 /  (p ¼ 0.885).
Importantly, there was no detectable aberrant DNA methyl-
ation in control thymocytes isolated from age-matched ElSR-
tTA;p53
 / ,E lSR-tTA;Teto-Cre;Pten
LoxP/LoxP,o rElSR-tTA;E2f2
 / 
mice (unpublished data). The aberrant DNA methylation
detected in tumor samples was conﬁrmed by 126 COBRA
reactions performed on the same tumor samples that were
used for RLGS analysis. This analysis revealed that in 74% of
the cases evaluated, RLGS and COBRA assays yielded
identical results (Figure S5 and unpublished data). In 22 %
of cases COBRA detected aberrant DNA methylation events
that were not identiﬁed by RLGS. This is not surprising, since
COBRA is a more sensitive method to detect DNA methyl-
ation. In 4% of cases, COBRA assays failed to detect DNA
methylation events that were detected by RLGS; this
discrepancy likely reﬂects the different restriction sites
analyzed by these methods.
Side-by-side comparison of DNA methylation proﬁles
between deleted and nondeleted tumor groups could
distinguish three classes of DNA methylation events (Figure
5A). The ﬁrst class included aberrant DNA methylation events
that were common between deleted and nondeleted tumor
cohorts, with methylation of some CpG islands occurring in
all tumor groups irrespective of the particular tumor
suppressor deleted. The second class consisted of aberrant
DNA methylation events that were suppressed by loss of
tumor suppressor function, with some DNA methylation
events suppressed only in speciﬁc tumor suppressor cohorts
and others events suppressed in all tumor suppressor cohorts.
Conversely, the third class consisted of novel DNA methyl-
ation events that occurred in tumors as a result of tumor
suppressor inactivation (Class I, Class II, and Class III; Figure
5A). An evaluation of gene expression in each tumor
suppressor cohort indicated that suppression of promoter
methylation correlates well with their reactivation of ex-
pression. For example, expression of 6D20,w h i c hw a s
methylated and silenced in 50% of MYC-initiated tumors,
was preferentially reactivated in tumors deﬁcient either for
E2f2, p53,o rPTEN (Figure 4D). Similarly, expression of seven
prior to sorting (unsorted), and after sorting (EGFP-negative [ ] and EGFP-positive [þ] cells) are shown. The purity of EGFP-negative and EGFP-positive
populations sorted from either side of the threshold, which is indicated with dotted lines, is shown within each panel.
(C) Real-time RT-PCR analysis of MYC and nucleolin (nuc) expression in unsorted (gray bars), EGFP-positive (black bars) and EGFP-negative (white bars)
cell populations sorted from thymocytes of ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXPEGFP mouse as described in Figure 2B. Expression data are presented
as fold increase relative to the EGFP-negative population. Representative example from three independent experiments is shown.
(D) Representative examples of RLGS profile sections derived from cells isolated as described in Figure 2B. The arrows indicate the position of RLGS
fragments that appear methylated in tumors.
(E) No differences in CpG methylation profiles between EGFPþand EGFP cell populations were detected for any of the three pairs of samples analyzed
as summarized in Figure 2E where open boxes indicate no methylation at that site. Frequency of methylation events in final tumors for each RLGS
fragment is shown as a percentage in corresponding boxes.
(F) COBRA analysis of bisulfite-treated DNA isolated from EGFP-negative [ ] and EGFP-positive [þ] thymocytes of three quadruple transgenic mice at age
21 d. PCR products for RLGS fragment 3F70 were digested with restriction enzyme BstUI and loaded onto a PAGE gel along with 100% methylated (SssI-
treated DNA) control (100%). DNA from normal thymocytes (con) and two tumors is also shown. Undigested and digested fragments correspond to
unmethylated and methylated DNA, respectively.
(G) Expression of genes near the RLGS fragments as determined by real-time RT-PCR analysis of EGFP-negative (white bars) and EGFP-positive (black
bars) cell populations sorted from thymocytes of ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP
EGFP. Expression of each gene in EGFP-positive population is
presented as fold decrease relative to the expression of the same gene in EGFP-negative population. Representative examples from three independent
experiments are shown.
doi:10.1371/journal.pgen.0030167.g002
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3F45, 3F56, 4B22, 1G05–06, 1D14, and 6C25 correlated well
with the methylation status of CpG islands in each corre-
sponding genetic group (Figure 4E). Additional genetic
changes in the evolving tumors likely account for the few
cases where expression and DNA methylation proﬁles did not
correspond (see 1D14, p53
 /  for an example). These data
suggest that tumor suppressor–speciﬁc patterns of CpG
island methylation correspond with global gene expression
proﬁles.
As a measure of CpG methylation speciﬁcity provoked by
the inactivation of individual tumor suppressor pathways, we
performed a two-dimensional unsupervised hierarchical
cluster analysis. This unbiased analysis of DNA methylation
identiﬁed deleted (p53
 / , Pten
 / , and E2f2
 / ) and nondeleted
tumor groups correctly (Figure S6). Strikingly, unsupervised
hierarchical clustering performed with all tumor samples
together led to an almost perfect segregation of tumors based
on their genetic background (Figure 5B). While the entire
constellation of methylation changes (or lack thereof) can
serve to discriminate between genetic groups, it is clear from
the data shown in Figure 5A that different methylation events
contribute to different degrees. The contribution of each
DNA methylation event to the clustering observed in Figure
5B was evaluated by a Random Forrest analysis and statistical
ranking (see Table S4). Two important conclusions can be
drawn from these experiments. The ﬁrst and perhaps most
obvious of these is that loss of tumor suppressor functions
yield speciﬁc proﬁles of CpG island methylation in cancer.
We view these results to mean that different tumor
suppressor pathways impose unique selective pressures on
neoplastic cells that drive the speciﬁcity of CpG island
methylation. Interestingly, the overall frequency of hyper-
methylated CpG islands in Pten-deﬁcient tumors was sub-
stantially less than seen in the other tumor cohorts (0.3%, p¼
0.004), suggesting a particularly strong diversion of the
selective pressure in the evolution of Pten
 /  tumors. This
suppression of tumor-speciﬁc DNA methylation by loss of
Pten is likely a reﬂection of the broader number of pathways
that Pten action impacts to prevent tumorigenesis [33]. The
second conclusion is that the speciﬁcity of CpG island
methylation is not likely to be a consequence of a general
Figure 3. Aberrant DNA Methylation in Mouse Embryonic Fibroblasts
Transformed with Myc and Ras
(A) Schematic representation of experimental design used for evaluation
of in vitro and in vivo DNA methylation in MEFs. Early passage of primary
MEFs was either harvested (C0) or infected with retroviral vectors
expressing MYC and an activated form of Ras (Ras
61L). A portion of cells
was harvested immediately after transformation had occurred, as
determined by morphological changes (C1). At this point, the rest of
the cells was either injected subcutaneously into nude mice or kept in
culture. By 18 d, injected cells formed tumors that were harvested along
with C1 cells kept in culture in vitro (T2 tumor and C2 culture,
respectively).
(B) Methylation status of 1,635 NotI restriction sites was evaluated by
RLGS in DNA from C0, C1, and C2 cultures along with five T2 tumors
derived from nude mice. The Venn diagram shows the number of NotI
fragments that became methylated in T2 culture and T2 tumors. Sections
of RLGS profiles are shown for fragments 3B29 and 4F01.
(C) Summary of DNA methylation changes observed in C0, C1, and C2
culture and five T2 tumors as determined by RLGS. Open squares
represent unmethylated sequences, black squares represent methylated
events.
doi:10.1371/journal.pgen.0030167.g003
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Hypermethylation and Genetic Makeup of Tumorsdefect in the DNA methylation machinery since the speciﬁc
proﬁle, but not the frequency, of tumor-dependent CpG
methylation events is altered by the loss of p53 or E2f2.
Discussion
In this study, we have investigated the interplay between
genetic mutations and the establishment of global DNA
methylation patterns in the development of mouse T cell
lymphomas. The model used here, developed by Felsher and
colleagues, uses high levels of MYC expression to mimic
similar events taking place during human lymphomagenesis
such as in Burkitt’s lymphoma ([34] and references therein).
The clear advantage of using a mouse model to study the role
of DNA methylation in cancer is that cohorts used are
genetically homogeneous in all respects except on a deﬁned
set of genetic variables (i.e., overexpression of MYC). There-
fore, we consider this mouse model to be suitable for studying
the relationship between genetic and epigenetic changes
during tumor development. We demonstrate that DNA
methylation patterns in these tumors are characterized by
frequent and nonrandom patterns, similar to what has been
described in human malignancies. These patterns are
exquisitely dependent on the genetic makeup of the tumor
cell, as homozygous deletion of either p53, Pten,o rE2f2 in
MYC-induced T cell lymphomas resulted in unique tumor-
speciﬁc patterns of genome-wide DNA methylation. This
analysis provides the ﬁrst clear-cut experimental evidence
showing that genetic background can drive the establishment
of aberrant DNA methylation proﬁles during lymphoma
development, offering an explanation for the tremendous
epigenetic heterogeneity observed in human cancer [4,15].
Multiple mechanisms have been proposed to explain the
speciﬁcity of aberrant DNA methylation in human cancer,
including the differential susceptibility of DNA sequences to
methylation [8–10] and the targeting of methyltransferase
activity to speciﬁc promoter sequences [12,13]. The fact that
our RLGS analysis identiﬁed a speciﬁc signature of CpG
island methylation that could only be detected late in the
MYC-induced neoplastic process suggests that MYC over-
expression is insufﬁcient to target the DNA methylation
machinery to speciﬁc sites. It is unlikely that the absence of
aberrant promoter methylation early in the neoplastic
process was due to the notoriously slow nature of de novo
methylation relative to the kinetics of gene repression, since
repression was not observed at these early stages of disease,
either. This view is further supported by the absence of any
hypermethylation signature in cells immediately following
the transformation by MYC and Ras
61L. Rather, speciﬁc
patterns of DNA methylation could only be detected in
MYC/Ras
61L-transformed MEFs that have been either cultured
in vitro for an extended period of time or injected into nude
mice for an equally long time. However, we cannot rule out
that MYC-initiated targeting of the DNA methylation
machinery could occur as an infrequent aberrant event
during tumor development. Comparison of global methyl-
ation proﬁles between different mouse models of T cell
lymphomas would not only help to answer this question but it
would also address to what degree the global DNA methyl-
ation pattern is dependent on initial oncogenic insult.
The work described here provides an alternative explan-
ation for the longstanding question of tumor-speciﬁc CpG
island hypermethylation. We ﬁnd that tumor-speciﬁc signa-
tures of CpG island methylation can only be detected late in
the neoplastic process, at a time when the clonal expansion of
pretumor cells can be observed, suggesting that speciﬁc
proﬁles of CpG island methylation arise from the expansion
of rare neoplastic cells. While we cannot rule out the
possibility that DNA methylation proﬁles of late-stage tumor
cells may indirectly reﬂect the selection of cells having a
unique expression proﬁle, our observation that inactivation
of different tumor suppressor pathways results in distinct
aberrant DNA methylation signatures indicates that rare
DNA methylation events are selected for during the course of
tumor development.
The function of genes silenced by hypermethylation is
expected to provide tumor cells with some selective advant-
age. Indeed, many of the hypermethylated genes identiﬁed by
RLGS have functions consistent with a tumor suppressor role,
including Id4 and Ptprk [22,35]. The observation that
inactivation of different tumor suppressor pathways results
in distinct aberrant DNA methylation signatures further
supports the notion that rare DNA methylation events are
selected for during the course of tumor development. We
envision that the function of genes that are no longer selected
for hypermethylation in each of the three tumor suppressor
cohorts studied here must be somehow related or dependent
on the function of the speciﬁc tumor suppressor targeted for
inactivation. The inactivation of Pten, for example, would
thus diminish the selective pressure imposed during neo-
plastic progression for genes involved in similar or related
functions. Comparison among the three tumor suppressor
cohorts suggested that this selection is strongly inﬂuenced by
the speciﬁc tumor suppressor inactivated in the tumor cell.
Remarkably, the strength of the inﬂuence that genetics has on
this selection mechanism is illustrated by the ability of
Figure 4. Analysis of Aberrant DNA Methylation in p53 , E2f2 , and Pten-Deleted Lymphomas
(A) Graphical representation of the time-frame of tumor onset in ElSR-tTA;Teto-MYC (wild type), ElSR-tTA;Teto-MYC;p53
 /  (p53
 / ), ElSR-tTA;Teto-
MYC;E2f2
 /  (E2f2
 / ), or ElSR-tTA;Teto-MYC;Teto-Cre;Pten
LoxP/LoxP (Pten
 / ) mice.
(B) Examples of FACS profiles of normal thymocytes (normal) and tumor cells (tumors) derived from the different genetic backgrounds as indicated. The
percentage of cells that are in each quadrant of the FACS profile is indicated.
(C) Representative examples of RLGS profile sections of normal thymocytes derived from ElSR-tTA (normal p53
þ/þ) and ElSR-tTA; p53
 / (normal p53
 / )
mice and tumors derived from ElSR-tTA;Teto-MYC (tumor p53
þ/þ) and ElSR-tTA;Teto-MYC; p53
 /  (tumor p53
 / ) mice. The position of DNA fragment
2D17 is indicated with arrows. Note the increase in the intensity of 2D17 in tumors deleted for the p53 tumor suppressor (compare p53
þ/þ and p53
 / 
tumor samples in the third and fourth panels).
(D) Real time RT-PCR analysis of expression of 6D20 in normal thymic controls (white bars), ElSR-tTA;Teto-MYC tumors (black bars), or ElSR-tTA;Teto-MYC
tumors deleted either for p53, E2f2,o rPten (grey bars) as indicated.
(E) Summary of expression data from tumors derived in different genetic backgrounds obtained on analysis of eight RLGS fragments as indicated. Red
boxes represent tumors with reduction in expression relative to normal thymic controls; yellow boxes indicate tumors with no change in expression.
Repression thresholds for individual genes were chosen as described in Materials and Methods.
doi:10.1371/journal.pgen.0030167.g004
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suppressor status in each tumor. We would predict that the
nature of the initiating oncogenic insult, in this case MYC,
would have an equally important role in determining the
CpG methylation proﬁle of the emerging tumor.
It is clear from in vitro experiments and more recent
genome-wide sequencing efforts that the transformation of
both human and mouse cells to a malignant phenotype
requires multiple sequential genetic lesions. In the context of
an evolving tumor, it is likely that the initial genetic insult
acts as a driving force for the ﬁrst round of epigenetic
alterations and that subsequent genetic alterations as the
tumor evolves lead to further epigenetic selection. There is
also evidence that epigenetic alterations inﬂuence the
Figure 5. Loss of Tumor Suppressor Genes Redirects the Course of Aberrant DNA Methylation
(A) Comparison of tumor-specific DNA methylation changes observed in ElSR-tTA;Teto-MYC;p53
 / (left panel), ElSR-tTA;Teto-MYC;E2f2
 / (middle panel),
and ElSR-tTA;Teto-MYC; Teto-Cre;PtenLoxP/LoxP (right panel) mice relative to ElSR-tTA;Teto-MYC mice (indicated as p53
þ/þ, E2f2
þ/þ, and Pten
þ/þ in each of
the panels). Data is shown for RLGS fragments methylated in .33% of tumors. Filled boxes indicate methylation and open boxes indicate a loss of
methylation at those sites. Class I, Class II, and Class III RLGS DNA fragments are outlined in green, red, and blue, respectively). Data from analysis of
thymocytes isolated from two age-matched normal control ElSR-tTA;p53
 /  ( / ; left panel), ElSR-tTA;E2f2
 /  ( / ; middle panel), and ElSR-tTA;Teto-
Cre;Pten
LoxP/LoxP ( / ; right panel) mice are also shown. Fisher’s exact test was applied and p-values are shown.
(B) Dendrogram of a two-dimensional unsupervised hierarchical cluster analysis for 28 tumors analyzed using methylation status of 1,481 NotI
fragments. Control (ElSR-tTA;Teto-MYC), p53 (ElSR-tTA;Teto-MYC; p53
 / ), E2f2 (ElSR-tTA;Teto-MYC; E2f2
 / ), or Pten (ElSR-tTA;Teto-MYC; Teto-
Cre;PTEN
LoxP/LoxP).
doi:10.1371/journal.pgen.0030167.g005
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that the hypermethylation and silencing of the mismatch
repair gene MLH1 leads to microsatellite instability in colon
cancer [36,37]. Similarly, the silencing induced by promoter
hypermethylation of the Werner syndrome gene that occurs
in several human cancer types, leads to chromosomal
instability and apoptosis [38]. Thus, the coevolution of
genetic and epigenetic changes during the transformation
of a normal cell may be viewed to fuel the diversity of tumor
phenotypes. This interpretation is consistent with the
heterogeneity of DNA methylation we observe even within a
single genetic cohort of mouse lymphomas.
While the underlying mechanisms for this selection process
are unknown, one could speculate that due to the loss of
tumor suppressor function, gene-expression proﬁles are
changed. These changes in gene expression may trigger a
cascade of epigenetic events including nucleosome reposi-
tioning, histone tail modiﬁcations, and subsequently DNA
methylation [39–41]. There is indeed evidence that a similar
mechanism for the speciﬁcity of CpG island methylation is
also operative in human malignancies. For example, Weisen-
berger et al. described the tight association of BRAF mutation
with a CpG island methylator phenotype in colon cancer [19],
and it is known that in breast cancers with either BRCA1 or
BRCA2 mutations stable epigenetic changes reﬂect gene-
expression proﬁles in these cells [42–44]. In conclusion, our
ﬁndings suggest that genetic events can determine the course
in the epigenetic evolution of DNA methylation during
tumor development.
Materials and Methods
Generation and maintenance of mice. The E2f2
 / , Teto-Cre, and
ElSR-tTA;Teto-MYC mice were obtained from Stuart Orkin (Harvard
Medical School, Boston, Massachussetts), Andreas Nagy (Samuel
Lunenfeld Research Institute, Toronto, Canada) and Dean W.
Felsher (Stanford University, Stanford, California), respectively.
Mice carrying the conditional Pten allele (Pten
LoxP) were a generous
gift from Michael Weinstein (The Ohio State University, Columbus,
Ohio). Mice carrying Rosa26LOXP
EGFP allele (C57BL/6J background)
were purchased from The Jackson Laboratory. Genomic DNA
isolated from mouse tails was used in PCR-based genotyping. For
this study, standard genetic crosses were used to generate ElSR-
tTA;Teto-MYC, ElSR-tTA;Teto-MYC; E2f2
 / , ElSR-tTA;Teto-MYC;p53
 / ,
ElSR-tTA;Teto-MYC;Teto-Cre, Pten
LoxP/LoxP, and ElSR-tTA;Teto-MYC;Te-
to-Cre;Rosa26LOXP
EGFP mice. ElSR-tTA;Teto-MYC mice were kept on
a clean FVB/NJ genetic background. Tumor studies involving p53
 ,
E2f2
  or Pten
LoxP alleles were performed with mice backcrossed into
FVB/NJ mouse strain for ﬁve times (ﬁfth generation). Mice of
appropriate genotypes were monitored and harvested at the
terminal stage as judged by the overall health of mice. Normal
thymi or thymic tumor masses were homogenized to obtain single-
cell suspensions from which red cells were removed using hypotonic
cell lysis buffer (BD Pharmingen). Aliquots of cells were snap frozen
in liquid nitrogen and used for DNA and RNA isolation as described
below.
DNA isolation. Genomic DNA was isolated as described previously
[45]. Brieﬂy, 20–25 ml of preheated lysis buffer (150 mM EDTA pH
8.0, 10mM Tris HCl pH 8.0, and 1% Sarkosyl) was used to dissolve the
tissue at 55 8C until the solution became homogenous. An equal
amount of phenol:chloroform:isoamylalcohol (50:24:1) was used to
extract the genomic DNA. Dialysis of the DNA solution was
performed in 10 mM Tris HCL pH8.0 buffer overnight, and RNA
was subsequently removed by digestion with RNaseA (500 lg/ml).
Genomic DNA was precipitated with ethanol, dissolved in TE buffer,
and stored at 4 8C.
RLGS. RLGS was performed according to the published protocol
[46]. Brieﬂy, 7 lg of DNA sample was used in each reaction. The ends
of the sheared DNA were blocked with the addition of nucleotide
analogs (aS-dGTP, aS-dCTP, ddATP, and ddTTP) using T4 DNA
polymerase. DNA was then digested with 20 U of NotI enzyme
(Promega) and generated sticky ends were ﬁlled in with [a-
32P]dCTP
and [a-
32P]dGTP. The labeled DNA was then digested with 20 U
EcoRV (Promega) and 0.7 lg was run on 0.8% agarose tube gel (ﬁrst
dimension separation) at 230 V for about 20 h. After electrophoresis,
the DNA in the agarose gel was digested with 750 U of HinfI
restriction enzyme (Promega) and then electrophoresed into 5%
polyacrylamide gel (second dimension separation) at 150–180 V for
18–20 h. The gel was dried and autoradiography was performed on an
X-ray ﬁlm in the presence of one Quanta III intensifying screen
(DuPont) at  80 8C for 3–21 d.
RLGS gel analysis. RLGS proﬁles obtained from tumors of
different genotypes were compared to the proﬁles obtained from
thymocytes of age-matched normal mice. RLGS fragments present in
the proﬁles of normal thymocytes and absent or reduced in intensity
in tumor proﬁles as determined by visual inspection relative to
several neighboring unaltered NotI fragments were scored as DNA
methylation events. Each RLGS proﬁle was analyzed two times by
independent investigators in a blinded fashion and loss events were
scored only if the score was concordant between the two analyses.
Loss events were scored as DNA methylation events regardless of the
degree of intensity loss. RLGS fragments that were changed at least
once within a genetic group from the initial analysis were
subsequently marked for second round analysis to insure accuracy
of obtained data. To avoid scoring polymorphic changes as DNA
methylation events, all spots that showed variable intensity between
RLGS proﬁles derived from FVB/NJ, 129SvIMJ, or C57BL/6J strains
were removed [22].
Southern blotting. A total of 10 lg of genomic DNA isolated from
normal thymocytes or thymic tumors was digested with NotI and
EcoRV (New England Biolabs). Following electrophoretic separation
using 0.8% agarose gels and transfer to GeneScreen nylon mem-
branes (Perkin-Elmer), the digested DNA was probed with
[a-
32P]dCTP radioactively labeled NotI-EcoRV DNA fragment as
described before [47].
Bisulﬁte genomic sequencing and COBRA. One microgram of
genomic DNA from tumors and normal controls was treated with
sodium bisulﬁte according to published protocols [48]. Primers were
designed to allow ampliﬁcation of both methylated and unmethylated
DNA. The sequences of primers used for each of the RLGS derived
NotI-EcoRV fragments are listed in Table S3. For COBRA, the PCR
product was digested using 10 U of restriction enzyme BstUI and
separated on 8% polyacrylamide gel. For bisulﬁte sequencing, the
PCR products were subcloned using the TOPO TA-Cloning kit
(Invitrogen). Ten clones for each sample were sequenced using ABI
big dye chemistry and compared to original genomic DNA sequence
using Seqman 6.1 software (DNASTAR).
FACS. ElSR-tTA;Teto-MYC;Teto-Cre;Rosa26LOXP
EGFP mice were
harvested at age 21, 31, or 42 d and thymocytes isolated from these
mice were sorted for EGFP-positive and EGFP-negative cells using
high-speed sorting with FACS Aria (Becton Dickinson). DNA and
RNA was extracted from sorted cells and analyzed by RLGS and real-
time RT-PCR. Lymphomas from terminally sick mice were charac-
terized by using FACS. Brieﬂy, single-cell suspensions prepared from
thymic tumor masses were stained with antibodies speciﬁc for mouse
T cells, B cells, myeloid and erythroid cells including anti-CD4, anti-
CD8, anti-CD3, anti-B220, anti-CD11b, and anti-TER119 antibodies
(BD Pharmingen). Stained cells were analyzed using FACSCalibur
ﬂow cytometer and CellQuest software (Becton Dickinson). All
tumors analyzed in this study were T cell lymphomas and were
negative for myeloid marker CD11b, B-cell marker B220, and
erythroid marker TER119.
Quantitative real-time RT-PCR. Thymi or tumor masses were
collected from mice of different ages and homogenized to obtain
single cell suspensions that were used for total RNA isolation with
TRIzol reagent according to manufacturer’s instructions (Life
Technologies). Two to 10 lg of total RNA were used to generate
cDNA using Superscript III reverse transcriptase (Invitrogen). Real-
time RT-PCR was performed using the BioRad iCycler PCR machine.
Each PCR reaction contained 2.0 ll of cDNA template, primers at a
concentration of 100 nM, and 13SYBR Green Reaction Mix (BioRad).
Reactions were performed in a ﬁnal volume of 25 ll in triplicate and
data were analyzed using the DCt method, where GAPDH served as
the internal control. Each PCR generated only the expected
amplicon, as shown by the melting-temperature proﬁles of the ﬁnal
products, gel electrophoresis, and sequencing. For Figure 4E, we
chose threshold of 3-fold of reduction if range of fold repression for
that gene in ElSR-tTA;Teto-MYC-derived tumors was less than 20-fold.
If the gene was more severely repressed in ElSR-tTA;Teto-MYC-
derived tumors (range exceeded 20-fold), we chose threshold of 5-fold
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Table S2.
Cell culture and retroviral infections. MEFs were isolated from
E13.5 embryos using standard methods. All cells were cultured in
DMEM with 15% fetal bovine serum. High titer retroviruses were
produced by transient transfection of pBABE-puro-MYC, pBABE-hygro
Ras
61L or pBABE vector plasmids into the Phoenix-Eco packaging cell
line using standard methods. MEFs were infected three times at 12-h
intervals with Phoenix cell supernatants containing 4 lg/ml of
Sequabrene (Sigma). Infected cells were then selected for a total of 5
d in the presence of 2.5 lg/ml of puromycin and 200 lg/ml of
hygromycin. At this point, cells infected with MYC/ Ras
61L retroviruses
showed transformed phenotype while cells infected with control virus
retainednormal phenotype. A portionof thesecells was harvestedand
used for DNA isolation (C1 culture and C0 culture, respectively;
Figure 3A). The rest of the MYC- and Ras
61L-transformed primary
MEFs was kept either in culture or resuspended in serum-free DMEM
mediumat a concentration 1310
7 cells/ml.Cells(100 ul) wereinjected
subcutaneously into therightand leftshouldersand hipsof each 8–10-
wk-old male athymic nude mouse. Tumors that developed in these
mice were harvested 18 d after injection along with MYC- and Ras
61L-
transformed primary MEFs kept in culture (tumors T2 and culture C2,
respectively; Figure 3A). Cells and tumors developed in nude mice
were used for DNA isolation and RLGS analysis.
Statistical analysis. DNA methylation frequencies in tumors
derived from ElSR-tTA;Teto-MYC, ElSR-tTA;Teto-MYC;E2f2
 / , ElSR-
tTA;Teto-MYC;p53
 / ,a n dElSR-tTA;Teto-MYC;Teto-Cre;Pten
LoxP/LoxP
mice were compared across using nonparametric Kruskal-Wallis
rank sum test [49]. Pair-wise comparisons of tumors deleted for either
p53, E2f2,o rPten with those derived from ElSR-tTA;Teto-MYC mice
were done by applying nonparametric Wilcoxon procedure [49] and
were corrected for multiple comparisons with Bonferroni correction.
A p-value , 0.0167 (0.05/3) was considered to be signiﬁcant. Survival
time data was analyzed the same way as above since there were no
censored observations. Under the assumption that all samples within
each group have the same frequency of methylation, the hetero-
geneity of DNA methylation frequencies across samples within each
tumor group was assessed by comparing mean methylation frequen-
cies to its variance using a chi-square statistic. Preferential
methylation of RLGS fragments within each group was assessed
under the null hypothesis of equal methylation frequencies for each
fragment, using a goodness-of-ﬁt test based on 10,000 random
simulations. Hierarchical cluster analysis of samples was performed
by applying phi-correlation coefﬁcient [50] similarity metric with
average linkage method, using all RLGS data with at least one
methylation event across the respective samples. For each RLGS
fragment, proportion of methylation between tumors from ElSR-
tTA;Teto-MYC group and tumors derived from ElSR-tTA;Teto-
MYC;E2f2
 / , ElSR-tTA;Teto-MYC;p53
 / ,o rElSR-tTA;Teto-MYC;Teto-
Cre;Pten
LoxP/LoxP groups, respectively, was compared by applying
Fisher’s exact test [49]. In order to identify RLGS fragments that
showed an increase in methylation events compared to overall
average methylation in the ElSR-tTA;Teto-MYC RLGS proﬁles, exact
Binomial test [49] was applied.
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